SVB Leerink Lowers Bluebird Bio (NASDAQ:BLUE) Price Target to $8.00
SVB Leerink Lowers Bluebird Bio (NASDAQ:BLUE) Price Target to $8.00
bluebird bio (NASDAQ:BLUE – Get Rating) had its price target reduced by SVB Leerink from $9.00 to $8.00 in a research note issued to investors on Monday, Benzinga reports. They currently have a market perform rating on the biotechnology company's stock. SVB Leerink also issued estimates for bluebird bio's Q4 2022 earnings at ($1.18) EPS, FY2022 earnings at ($5.13) EPS, Q1 2023 earnings at ($0.64) EPS, Q2 2023 earnings at ($0.62) EPS, Q3 2023 earnings at ($0.58) EPS, Q4 2023 earnings at ($0.48) EPS, FY2023 earnings at ($2.31) EPS and FY2024 earnings at ($1.59) EPS.
据Benzinga报道，在周一发布给投资者的一份研究报告中，SVB Leerink将蓝鸟生物(纳斯达克：Blue-Get评级)的目标价从9.00美元下调至8.00美元。他们目前对这家生物技术公司的股票进行了市场表现评级。SVB Leerink还发布了对蓝鸟生物2022财年第四季度每股收益(1.18美元)、2022财年每股收益(5.13美元)、2023年第一季度每股收益(0.64美元)、2023年第二季度每股收益(0.62美元)、2023年第三季度每股收益(0.58美元)、2023年第四季度每股收益(0.48美元)、2023财年每股收益(2.31美元)和2024财年每股收益(1.59美元)的预期。
Several other equities analysts also recently weighed in on the company. Royal Bank of Canada lowered their target price on bluebird bio to $8.00 and set a sector perform rating on the stock in a research report on Tuesday, November 8th. StockNews.com began coverage on bluebird bio in a research report on Wednesday, October 12th. They issued a sell rating on the stock. Three analysts have rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of Hold and a consensus price target of $6.75.
其他几位股票分析师最近也对该公司进行了分析。11月8日，加拿大皇家银行在一份周二的研究报告中将蓝鸟生物的目标价下调至8.00美元，并对该股设定了行业表现评级。StockNews.com在10月12日星期三的一份研究报告中开始报道蓝鸟生物。他们对这只股票发布了卖出评级。三位分析师对该股的评级为卖出，六位分析师给出了持有评级，一位分析师给出了买入评级。根据MarketBeat的数据，该股目前的平均评级为持有，共识目标价为6.75美元。
bluebird bio Stock Performance
蓝鸟生物股票表现
NASDAQ BLUE opened at $6.23 on Monday. The company has a market capitalization of $516.61 million, a PE ratio of -1.02 and a beta of 0.99. The business's fifty day moving average is $7.36 and its 200 day moving average is $6.52. bluebird bio has a fifty-two week low of $2.87 and a fifty-two week high of $8.58.
纳斯达克蓝周一开盘报6.23美元。该公司市值为5.1661亿美元，市盈率为-1.02，贝塔系数为0.99。该业务的50日移动均线切入位为7.36美元，200日移动均线切入位为6.52美元。蓝鸟生物的52周低点为2.87美元，52周高位为8.58美元。
Insider Transactions at bluebird bio
蓝鸟生物的内幕交易
In other news, Director Nick Leschly sold 4,290 shares of bluebird bio stock in a transaction dated Wednesday, January 11th. The stock was sold at an average price of $7.80, for a total value of $33,462.00. Following the sale, the director now directly owns 280,149 shares of the company's stock, valued at $2,185,162.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have sold 9,506 shares of company stock valued at $72,088. 2.90% of the stock is currently owned by insiders.
其他新闻方面，董事尼克·莱施利在一笔日期为1月11日星期三的交易中出售了4,290股蓝鸟生物股票。这只股票的平均售价为7.8美元，总价值为33,462.00美元。交易完成后，董事现在直接持有280,149股阿里巴巴股票，价值2185,162.20美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可在美国证券交易委员会网站。在过去的三个月里，内部人士已经出售了9,506股公司股票，价值72,088美元。该公司2.90%的股份目前由内部人士持有。
Institutional Investors Weigh In On bluebird bio
机构投资者参与蓝鸟生物
Large investors have recently made changes to their positions in the company. Metropolitan Life Insurance Co NY increased its stake in bluebird bio by 142.4% during the third quarter. Metropolitan Life Insurance Co NY now owns 4,671 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 2,744 shares during the last quarter. Amalgamated Bank bought a new stake in bluebird bio during the first quarter worth approximately $39,000. PEAK6 Investments LLC bought a new stake in bluebird bio during the second quarter worth approximately $41,000. US Bancorp DE grew its stake in shares of bluebird bio by 82.9% during the first quarter. US Bancorp DE now owns 8,486 shares of the biotechnology company's stock valued at $41,000 after buying an additional 3,847 shares during the last quarter. Finally, Keybank National Association OH bought a new position in shares of bluebird bio during the second quarter valued at approximately $42,000. 79.01% of the stock is owned by institutional investors.
大型投资者最近对他们在该公司的头寸进行了调整。纽约大都会人寿保险公司在第三季度增持了蓝鸟生物的股份142.4%。纽约大都会人寿保险公司在上个季度增持了2,744股后，现在拥有4,671股这家生物技术公司的股票，价值30,000美元。合并银行在第一季度购买了蓝鸟生物的新股份，价值约3.9万美元。Peak6 Investments LLC在第二季度购买了蓝鸟生物的新股份，价值约41,000美元。US Bancorp DE在第一季度增持了蓝鸟生物的股份82.9%。US Bancorp DE现在持有这家生物技术公司8486股股票，价值4.1万美元，此前在上个季度又购买了3847股。最后，KeyBank National Association OH在第二季度购买了蓝鸟生物的新头寸，价值约42,000美元。79.01%的股票由机构投资者持有。
bluebird bio Company Profile
蓝鸟生物公司简介
(Get Rating)
(获取评级)
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.
蓝鸟生物公司是一家生物技术公司，研究、开发和商业化针对严重遗传病的变革性基因疗法。其用于治疗严重遗传性疾病的候选产品包括用于治疗输血依赖型β-地中海贫血的贝替贝吉基因Autotemcel；用于治疗镰状细胞病(SCD)的lovotieglogene autemcel；以及用于治疗大脑肾上腺脑白质营养不良的伊利伐多烯Autotemcel。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on bluebird bio (BLUE)
- The Future Of E-Commerce: Analysis And New Data
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- Levi Strauss Is A Good Fit For Income Investors
- 3 Small Caps That Have Big Upside
- Mullen Automotive: The Good News, The Bad And The Ugly Outlook
- 免费获取StockNews.com关于蓝鸟生物的研究报告(蓝色)
- 电子商务的未来：分析和新数据
- 雪佛龙以750亿美元的股票回购取悦股东
- 列维·施特劳斯非常适合收益型投资者
- 3只小盘股有很大的上涨空间
- 马伦汽车：好消息、坏消息和丑陋的前景
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.
获得蓝鸟生物日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对蓝鸟生物和相关公司的最新新闻和分析师评级的每日简明摘要。
译文内容由第三方软件翻译。